ALS posts a sharp lift in profitability for FY26, with statutory net profit after tax rising 24.4% to $318.7 million as commodities testing demand remains strong. Investors also see the company lean on hefty free cash generation and dividends, signalling confidence in the outlook.
ALS reports that full-year revenue climbs 10.7% to $3.32 billion, while underlying earnings before interest and tax increase 19.3% to $599 million. Free cashflow hits $674.1 million, giving the group more than $580 million in pro-forma available liquidity to deploy. A full-year dividend of 23.1 cents per share is declared, returning part of that cash to shareholders.
Minerals testing sits at the heart of the result, with ALS pointing to 20.2% organic revenue growth in that business as the main earnings driver. Life sciences operations also expand organically, helped by food testing demand in Europe and Asia.
Those gains help counter more uneven trading in environmental and pharmaceutical testing, where performance is described as mixed. Together, the divisions keep overall growth momentum intact.
Guidance for FY27 calls for mid to high single digit organic revenue growth across the group, suggesting ALS expects conditions to stay supportive rather than spectacular. Management frames this positioning as a buffer against supply chain risks linked to conflict in the Middle East, aiming to avoid material shortages and keep direct cost impacts contained.
Potential earnings exposure from those disruptions is estimated at between $5 million and $10 million, which is manageable against current profit levels.
